Neovasc Inc. (NVCN)
(Delayed Data from NSDQ)
$0.50 USD
+0.01 (2.96%)
Updated May 3, 2019 03:59 PM ET
After-Market: $0.49 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$0.50 USD
+0.01 (2.96%)
Updated May 3, 2019 03:59 PM ET
After-Market: $0.49 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Neovasc (NVCN) is on the Move, Here's Why the Trend Could be Sustainable
by Zacks Equity Research
Neovasc (NVCN) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Recent Price Trend in Neovasc (NVCN) is Your Friend, Here's Why
by Zacks Equity Research
Neovasc (NVCN) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Terex and Armstrong World Industries have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Terex and Armstrong World Industries are part of the Zacks Bull and Bear of the Day article.
3 Medical Instruments Stocks on Recovery Path After Dismal 2022
by Indrajit Bandyopadhyay
Here we discuss three medical instruments stocks - TCMD, VCYT and NVCN - that have started to recover in the past few months after declining for the major part of 2022.
Neovasc (NVCN) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Neovasc (NVCN) delivered earnings and revenue surprises of -6.38% and 7.70%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Avanos Medical (AVNS) Surpasses Q2 Earnings Estimates
by Zacks Equity Research
Avanos Medical (AVNS) delivered earnings and revenue surprises of 5.13% and 2.47%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Asensus Surgical (ASXC) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Asensus Surgical (ASXC) delivered earnings and revenue surprises of 12.50% and 20.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Mesa Labs (MLAB) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Mesa Labs (MLAB) delivered earnings and revenue surprises of -40% and 4.14%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
OrthoPediatrics (KIDS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
OrthoPediatrics (KIDS) delivered earnings and revenue surprises of -13.33% and 0.18%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Neovasc (NVCN) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Neovasc (NVCN) delivered earnings and revenue surprises of -140.80% and 23.63%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aspira (AWH) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aspira (AWH) delivered earnings and revenue surprises of 0% and 5.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
908 Devices Inc. (MASS) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
908 Devices Inc. (MASS) delivered earnings and revenue surprises of 0% and 8.55%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
LENSAR, Inc. (LNSR) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
LENSAR, Inc. (LNSR) delivered earnings and revenue surprises of 23.86% and 4.80%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Integer (ITGR) Lags Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Integer (ITGR) delivered earnings and revenue surprises of -12.36% and 1.33%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Hologic (HOLX) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 33.55% and 12.60%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Neovasc (NVCN) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Neovasc (NVCN) delivered earnings and revenue surprises of -22.22% and -41.42%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Neovasc (NVCN) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Neovasc (NVCN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neovasc (NVCN) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Neovasc (NVCN) delivered earnings and revenue surprises of 0.00% and -36.70%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Neovasc (NVCN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Neovasc (NVCN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neovasc (NVCN) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Neovasc (NVCN) delivered earnings and revenue surprises of 60.00% and -24.67%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Neovasc (NVCN) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Neovasc (NVCN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neovasc (NVCN) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Neovasc (NVCN) delivered earnings and revenue surprises of 66.67% and -6.55%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Neovasc (NVCN) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Neovasc (NVCN) delivered earnings and revenue surprises of 3.77% and 13.82%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Neovasc (NVCN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Neovasc (NVCN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Neovasc (NVCN) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Neovasc (NVCN) delivered earnings and revenue surprises of -35.59% and -5.33%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?